Amos Adler has spent nearly two decades as founder and CEO of MEMOTEXT Corp, a digital patient engagement platform built to drive medication adherence through personalized, evidence-based messaging. He later co-founded A4i, a joint venture with CAMH supporting people living with schizophrenia through digital engagement, and is now building MTXT.ai, aimed at compressing the years-long gap between a validated research idea and an actual deployable health product.In this conversation, Amos traces how MEMOTEXT evolved from a single content-delivery engine, what would later be called a just-in-time adaptive intervention, into the toolkit behind dozens of patient engagement applications, and why he treats every accelerator, grant, and partnership as a long-term play rather than a quick win: in his world, next week is effectively five years away, and validation takes years no matter how good the idea is.We get into a genuinely counterintuitive finding from his own experience: Canadian IP terms for academic principal investigators are actually more favorable than American ones, yet Canadian founders still struggle to execute at the same speed, largely because the U.S. runs the equivalent of twenty separate CIHRs to Canada's one, with a customer base to match. Amos is blunt about where Canadian incubators and accelerators fall short: too many are staffed by people who've never built anything themselves, too many measure success by dollars raised rather than revenue or customer traction, and too few are willing to cut a startup loose when it isn't working. He contrasts that with Creative Destruction Labs' model, where if no mentor raises their hand for you, you're out, and argues that exact kind of accountability, letting bad ideas die instead of keeping them on life support indefinitely, is what's missing from Canadian innovation culture. The result, in his words, is a landscape full of zombie companies: neither funded enough to scale nor allowed to fail.He's equally direct about founders themselves. Many of the academic entrepreneurs he's worked with, including people literally curing cancer, have never been taught the basics of selling, and treat business development as beneath the science, when it's the only thing that actually gets an idea to a patient. Revenue, in his view, solves problems no amount of grant writing ever will.The conversation closes on the familiar resource pattern this show keeps circling back to, extended into new territory: Canada exports its raw materials, its ideas, its IP, its highly subsidized and highly educated people, then buys the finished product back at a markup, whether that's a car, a can of aluminum we already produced, or a drug developed here and commercialized somewhere else. Amos offers one genuine point of optimism: researchers displaced by recent U.S. funding cuts are starting to land in Canada, and he argues that's exactly the kind of investment Canada should be scaling aggressively, if the country can find the will to plan ten and twenty years out instead of defaulting to consensus and stability.This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact
